If the transcriptional repression described here for the GATA3 locus proves to be a general mechanism for PR-mediated target gene repression, it could set the rationale for the use of EZH2 inhibitors in order to prevent PR-driven breast cancer progression, by blocking the repression of tumor suppressor genes and promoting a more differentiated status of breast cancer cells. The gene discussed is EZH2; the disease is breast cancer.